Corvus Pharmaceuticals Operating Income

Corvus Pharmaceuticals (CRVS) currently reports a operating income of $-57M as of June 2026. That compares with $-36M in the prior-year period — down 60.3% year over year. Use the charts on this page to explore Corvus Pharmaceuticals's operating income history and peer comparisons.

Corvus Pharmaceuticals's operating income decreased from $-36M to $-57M — a 60.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Corvus Pharmaceuticals reported $-57M in operating income as of June 2026. That compares with $-36M in the prior-year period — down 60.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-57M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Corvus Pharmaceuticals, and consider following CRVS for alerts when major investors trade the stock.

Corvus Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-57M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CRVS with unrelated industries.